Advanced NSCLC Clinical Trials

24 clinical trials for Advanced NSCLC across international registries, including 7 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer — RECRUITING · PHASE2
• Evaluating the Preliminary Efficacy and Safety of JS207 in NSCLC After Progression Following Platinum-based Chemotherapy and Immunotherapy — RECRUITING · PHASE2
• A Study to Evaluate the Safety and Efficacy of HB0025 Injection in Patients With Advanced Solid Tumor — RECRUITING · PHASE1
• Neoantigen-based Peptide Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After First-line Treatment — RECRUITING · NA
• Neoantigen-loaded DC Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After Second-line Treatment — RECRUITING · PHASE2
• Neoantigen-loaded DC Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After First-line Treatment — RECRUITING · NA
• Neoantigen-based Peptide Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After Second-line Treatment — RECRUITING · PHASE2
• Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation — ACTIVE_NOT_RECRUITING · PHASE2
• An Open-label, Multicenter, Phase 1a/1b Study to Evaluate the Safety and Anti-tumor Activity of TT125-802 in Combination With Adagrasib, Osimertinib or Docetaxel in Patients with Advanced NSCLC — NOT_YET_RECRUITING · PHASE1
• Ningetinib in Advanced NSCLC Skipping Mutations With MET Exon 14 Skipping Mutations — WITHDRAWN · PHASE2
• Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer — TERMINATED · PHASE1
• Dose tapering and Early Discontinuation to InCreAse cosT-effictIveness Of immunotherapy for Non-small cell lung carcinoma trial number 1 (NVALT-30 - Dedication-1) — TERMINATED · PHASE3
• Real-World Study on Gene Profile in Patients With Advanced NSCLC Who Progressed on First-Line Osimertinib Therapy(GPS). — COMPLETED · PHASE4
• Nivolumab and Ipilimumab in Combination With Immunogenic Chemotherapy for Patients With Advanced NSCLC — ACTIVE_NOT_RECRUITING · PHASE1
• AST2818 in Advanced Non-Small Cell Lung Cancer With EGFR Mutations — TERMINATED · NA
• A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1) — NOT_YET_RECRUITING · PHASE2
• A Single-arm Pilot Study of Tislelizumab Combined With Anlotinib in Patients With Advanced NSCLC With Driver-negative After Progression to Immunotherapy — NOT_YET_RECRUITING · PHASE4
• Plasma miRNAs Predict Radiosensitivity of Different Fractionation Regimes in Palliative Radiotherapy for Advanced Non-small Cell Lung Cancer：Multicenter Controlled Study.(RadmiR-01) — COMPLETED · NA
• A Study to Evaluate Camrelizumab Combined With Famitinib as Subsequent Therapy in Patients With Advanced NSCLC — TERMINATED · PHASE3
• Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer — COMPLETED · PHASE1
• Clinical Sensitivity Verification Study of Circulating Tumor Cells Gene Mutation Detection From Advanced NSCLC Patients — OTHER
• Study of Thalidomide in Treatment of Advanced Nsclc (Dream-003) — OTHER · PHASE2
• POSITIVE - Study (Part III) Heidelberg — COMPLETED · NA
• Second-line Therapy Study of Combined Chemotherapy and Endostar to Patients With Non-Small Cell Lung Cancer(NSCLC) — OTHER · PHASE4

Refine this search